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Bartonella henselae wound-associated infections suggest involvement of extracellular matrix molecules in
adhesion and invasion. Pap31 was previously identified as a hemin-binding protein. Our recent studies suggest
the protein is an adhesin that is recognized by the host’s immune systems. In this study we examined the
interactions of B. henselae Pap31 with fibronectin (Fn), heparin (Hep), and human umbilical vein endothelial
cells (HUVECs). The cloned gene was expressed in Escherichia coli, and the purified Pap31 protein elicited
strong antibody responses in mice and was reactive with rabbit anti-live B. henselae and mouse anti-Pap31
antibodies by Western blotting. Pap31 bound to immobilized Fn and to HUVECs in a dose-dependent manner
and to Hep. Fn fragment-binding assays identified the Hep-1 and Hep-2 binding domains of human Fn and in
particular the 12-13FnIII repeat module as primary binding sites for this adhesin. Furthermore, Pap31 binding
to the above Fn fragments could be inhibited by Hep, suggesting a common binding site involving the 13FnIII
repeat module on the Hep-2 domain of Fn. Adherence of intact B. henselae to HUVECs was inhibited by
increasing concentrations of anti-Pap31 antibodies. In addition, purified Pap31 coprecipitated effectively with
Fn and anti-Fn antibodies. Taken together, these data suggest that Pap31 is an Fn-binding protein mediating
the B. henselae-host interaction(s), and they implicate the 13FnIII repeat module as an important binding site
for this adhesin on the Fn molecule. These interactions may be important initial steps leading to bacterial
attachment and colonization that promote the establishment of B. henselae infections in vivo.
The ability of bacteria to adhere to and colonize host cells is
mediated by specific interactions between bacterial surface
components (adhesins) and complementary host cell surface
receptors including the extracellular matrix (ECM) molecules
fibronectin (Fn) and heparin sulfate (HS). Fn is a glycoprotein
that binds several ECM molecules and is found in soluble form
in plasma and in fibrillar form in the ECM and basement mem-
branes. Glycosaminoglycans (GAGs) such as heparin (Hep) and
HS can also serve as putative receptors (1, 49). Hep and HS have
common structural features and participate in the GAG-medi-
ated recruitment of host ECM protein, a novel strategy in bacte-
rial adherence and invasion demonstrated by Duensing et al. (15).
HS, the most ubiquitous member of the GAGs, is found on the
surfaces of most eukaryotic cells as part of the ECM, whereas
Hep is synthesized in mast cells and basophils.
For several pathogens, the binding to ECM molecules such
as Fn and Hep is an important step in pathogenesis that in-
volves specific bacterial surface proteins (16, 26, 33, 47). This is
particularly true for wound-associated infections such as those
caused by Bartonella henselae. B. henselae, an opportunistic and
emerging pathogen, is carried by cats and causes several dis-
tinct clinical syndromes in immunocompetent individuals and
AIDS patients including cat scratch disease, bacillary angio-
matosis, chronic bacteremia, and valvular endocarditis (2, 10,
24, 31, 37, 40). While several lines of evidence indicate a role
for Fn in endovascular bacterial adherence during endocardial
infections (21, 30, 42), other results strongly point to multifac-
torial events of bacterial adherence as the cause of heart valve
damage (17).
B. henselae Pap31 was originally described as a bacterial
surface protein that is associated with the bacteriophage-like
particle from B. henselae (6). It is possible that this protein is
involved in packaging or phage particle assembly, or, alterna-
tively, it may be merely a surface protein that copurifies with
the particles. Pap31 is homologous to the multigene heparin-
binding protein (encoded by hbp) family in Bartonella quin-
tana, Neisseria opacity proteins (Opa), Brucella OMP31 (a pu-
tative porin), and Agrobacterium tumefaciens OMP25 (an
immunogenic surface protein) (34). HbpA, the most promi-
nent member of the Hbp family of proteins, has been reported
to play a role as a hemin receptor for B. quintana, and Opa
proteins in Neisseria gonorrhoeae promote adherence (4, 8, 20,
50). The aims of the present study were to express and purify
B. henselae Pap31; to characterize its binding to Fn, Hep, and
host cells; and to investigate the effect of anti-Pap31 on B.
henselae adherence to host cells.
MATERIALS AND METHODS
Bacteria, growth conditions, and reagents. B. henselae strain Houston-1
(ATCC 49882) was grown on tryptic soy plates supplemented with 5% sheep
blood in a humidified atmosphere at 37°C under 5% CO2. Escherichia coli
BL21(DE3)pLysS was grown in Luria-Bertani broth. The intact human Fn and
Fn fragments (Fig. 1), including the 30-kDa N-terminal heparin-binding frag-
ment (Hep-binding domain-1 [Hep-1]), the -chymotryptic 45-kDa collagen-
binding fragment, and the synthetic peptide (KNNQKSEPLIGRKKT) derived
from the C-terminal Hep-binding domain (Fn-PC), were purchased from Sigma
(St. Louis, MO). The -chymotryptic 40-kDa fragment, which contains the high-
affinity Hep-binding domain and part of the V region (connecting segment-1
[CS-1] site) of Fn (C-terminal Hep-binding domain-2 [Hep-2]), and the 120-kDa
cell-binding fragment were purchased from Chemicon International (Temecula,
CA). RetroNectin (Fn-RN), a chimeric peptide of human Fn comprising the
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central cell-binding domain (type III repeat, 8 to 10), the heparin-binding do-
main-2 (type III repeat, modules 12 to 14), and the CS-1 site, was purchased from
Takara Bio Inc. (Madison, WI) (Fig. 1).
B. henselae Pap31 expression and purification. For expression, the mature
Pap31 gene of B. henselae (without the putative promoter or leader signal
peptide) was directionally subcloned downstream of an isopropyl--D-thiogalac-
topyranoside (IPTG)-inducible T7/lac promoter and the initiation ATG of the
pCRT7/NT-TOPO expression vector (Invitrogen Corporation, Carlsbad, CA) to
produce recombinant Pap31 (rPap31). The recombinant plasmid was then used
to transform competent E. coli BL21(DE3)pLysS as described previously (12).
Expression was induced by addition of IPTG, and the fusion protein was purified
using the pRSET Xpress purification system (Invitrogen) according to the man-
ufacturer’s instructions. The identity of the purified protein was confirmed by
mass spectroscopy fingerprinting as described previously (12).
Abs. Antibodies (Abs) against B. henselae were produced by vaccinating rab-
bits with live B. henselae as described previously (12), and antisera against
purified Pap31 were produced in mice as described previously (19). Briefly, for
the production of anti-Pap31 polyclonal ascites, three CFW (Swiss Webster)
female mice weighing 21 g each (Charles River Laboratories) were injected
subcutaneously three times at 2-week intervals with 50 g of purified protein in
Freud’s incomplete adjuvant. Mice were boosted by intraperitoneal injection
following a satisfactory titer test. Blood was taken 3 days after the third immu-
nization, and mice were injected with a CFW sarcoma cell line (ATCC) in the
abdomen 7 days after the boost or injection. The mice were tapped at the onset
of visible ascite production and then humanely euthanized. Antibody titers were
assayed by enzyme-linked immunosorbent assay (ELISA) using microtiter plates
precoated with purified B. henselae Pap31 (Immulon 4 HB; Dynex Technologies,
Chantilly, VA) at 1 g/ml overnight at 4°C. The following day, the plates were
FIG. 1. Schematic representation of human plasma Fn, proteolytic fragments, and recombinant peptides of Fn used in this study. (A) Human
plasma Fn dimer showing the  and  subunits. The domains containing the known binding sites are indicated above the diagrams. The type I,
II, and III repeating structural domains of the Fn molecule are indicated as shown in the key. The 15 FnIII domain repeat modules are numbered,
and the RGD cell-binding motif and the spliced V region are indicated. The checkered box within the type III domain represents repeat module
13, which contains the high-affinity Hep-binding sequence. (B) Fn fragments Fn-30, Fn-40, Fn-45, and Fn-120 represent the Hep-1, Hep-2,
collagen-, and cell-binding domains, respectively. The purified Pap31 bound the Hep-1 and Hep-2 domains (Fig. 4C, bands 6 and 3, respectively)
but not the collagen- or cell-binding domains. Fn-30T and Fn-40T represent the two Hep-2 thermolytic fragments to which the purified Pap31
bound in overlay experiments (Fig. 4C, bands 5 and 3). Fn-PC is the synthetic peptide located at the C-terminal end of the 14FnIII repeat module.
Fn-RN (RetroNectin) is a chimeric peptide and is shown as represented on the Takara Bio Inc. website (46a), with the permission of the
manufacturer.
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blocked for 1 h with phosphate-buffered saline (PBS, comprising 137 mM NaCl,
2.7 mM KCl, 0.69 mM KH2PO4, and 6.4 mM Na2HPO4 [pH 7.4]) containing
0.05% Tween 20 and 1% bovine serum albumin (PBST-BSA) and were incu-
bated with antisera at doubling dilutions in blocking buffer, starting at 1:100 and
going up to 1:12,800. Wells were subsequently washed, and antigen-antibody
reactions were visualized using alkaline phosphatase-conjugated goat anti-mouse
immunoglobulin G (IgG) (1:5,000 in PBST-BSA) with para-nitrophenyl phos-
phate (Sigma, St. Louis, MO) as the substrate. Plates were read (optical density
at 450 nm) and adjusted for control wells.
Immunoblotting, proteolysis, and N-terminal amino acid sequencing. Outer
membrane proteins (OMPs) were prepared, and sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis were
performed as described previously (13). Limited proteolysis of human Fn with
thermolysin (Sigma, St. Louis, MO) was performed as described originally by
Sekiguchi and Hakomori (44). Briefly, 50 g of human Fn was incubated with
0.25 g of thermolysin at room temperature for 4 h, and the reaction was
terminated by addition of EDTA to a final concentration of 5 mM. The frag-
mented Fn was subjected to SDS-PAGE and either stained with Coomassie blue
or electrotransferred to a nitrocellulose membrane for ligand blotting. For ligand
blotting, transblotted membranes of purified Pap31 or thermolysin-fragmented
Fn were first blocked for 1 h with PBS containing 5% (wt/vol) nonfat dry milk
(PBSM) and then incubated for 2 h with human Fn (80 g/ml) or purified Pap31
(40 g/ml), respectively, in PBSM-T (PBSM containing 0.05% [vol/vol] Tween
20). Control blots were incubated with PBSM-T only. After three washes with
PBST, protein-associated Fn or Pap31 was detected with Fn- or Pap31-specific
polyclonal antibodies (primary antibodies) and alkaline phosphatase-conjugated
IgG as the secondary antibody. To determine surface exposure, B. henselae whole
cells (1-ml culture) in the mid-logarithmic phase of growth (optical density at 600
nm, 0.5 to 0.6) were pelleted by centrifugation, resuspended in 250 l of the
appropriate enzyme buffer, and treated with 50 g of protease (trypsin, chymo-
trypsin, or proteinase K [Sigma, St. Louis, MO]) for 1 h at 37°C as described
previously (13). The cells were washed three times with PBS and subjected to
SDS-PAGE and Western blot analysis using mouse anti-Pap31 antibodies. N-termi-
nal amino acid sequence analysis was performed by the Molecular Biology Resource
Facility of the University of Oklahoma Health Sciences Center (Oklahoma City) as
previously described (13).
ECM molecule binding assays. Fn-binding assays were performed by ELISA
according to Bauer and Spinola (3) using 96-well microtiter plates (Immulon 4
HB; Dynex Technologies, Chantilly, VA) coated overnight at 37°C with 100 l of
a 20-g/ml solution of Fn, Fn fragments, or fetuin, a highly glycosylated glyco-
protein control in coating buffer (0.25 M NaHCO3, 0.25 M Na2CO3 [pH 9.6]).
Wells were washed three times with PBST and blocked with 200 l of PBST
containing 2% BSA (Sigma, St. Louis, MO) for 2 h at 37°C. Purified Pap31 (10
g/ml) in PBS was added at 100 l per well, and the plates were incubated at
37°C for 1 h and washed three times with PBST to remove nonadherent proteins.
To detect bound proteins, wells were incubated with mouse anti-Pap31 ascites
(1:1,500) for 1 h at 37°C. After three washes with PBST, specific horseradish
peroxidase (HRP)-conjugated secondary Abs were used in the detection of Ab
binding. A colorimetric reaction was done with 3,3,5,5-tetramethylbenzidine at
0.1 mg/ml in conjunction with 0.01% (vol/vol) H2O2. For inhibition assays, a
mixture containing 1.6 M (29 g/ml) of Hep (sodium salt, porcine intestinal
mucosa; Sigma, St. Louis, MO) and Pap31 was added to wells precoated with Fn
and Fn fragments and then incubated for 1 h at 37°C as described above. All
experiments were performed twice and in triplicate. Treatment differences were
analyzed using the Student t test (46).
For Hep-binding assays, heparin Sepharose 6 Fast flow (Amersham Bio-
sciences, Piscataway, NJ) chromatography was used to investigate the interaction
between Hep and B. henselae Pap31. Essentially, Hep Sepharose 6 Fast flow
beads were equilibrated in binding buffer (10 mM sodium phosphate, pH 7.4)
and incubated with Pap31 at room temperature with gentle shaking for 2 h. The
mixture was then washed five times by centrifugation (6,000 g) for 2 min at 4°C
in binding buffer, and the Hep-bound proteins were eluted with 50 l of elution
buffer (10 mM sodium phosphate, pH 7.4, 1 M NaCl) and stored at 20°C un-
til use. The eluted proteins were subjected to SDS-PAGE and stained with
Coomassie blue. Fn and epidermal growth factor (EGF) (a protein with no
Hep-binding capability) were used as positive and negative controls, respectively.
Sepharose beads alone in binding buffer served as negative controls. Experiments
were performed twice and in triplicate, and treatment differences were tested by
Student’s t test (46).
Binding of purified Pap31 to host cells. Human umbilical vein endothelial cells
(HUVECs) were seeded (1.4  104) in endothelial growth medium—10% fetal
bovine serum (ATCC) in microtiter wells precoated with 0.2% gelatin and were
grown to confluence in a humidified atmosphere at 37°C under 5% CO2. The
following day, the seeded wells were washed three times with fetal calf serum-
free M199 medium, and either live B. henselae, B. henselae OMPs, purified Pap31
protein, or a fetuin control (3 g/well) diluted in M199 medium was added to
wells and incubated for 5 h in a humidified atmosphere at 37°C under 5% CO2.
The plates were washed three times as indicated above and fixed in 20% acetone
(150 l) for 10 min at room temperature. The excess acetone was removed from
the wells, and the plates were allowed to dry at 37°C overnight. For immunoas-
says, the acetone-fixed cells were probed with rabbit anti-B. henselae (1:8,000),
mouse anti-Pap31 ascites, or rabbit anti-fetuin (Sigma, St. Louis, MO; 1:1,600)
diluted in PBSM-T, followed by HRP-conjugated goat anti-rabbit or anti-mouse
IgG (Sigma, St. Louis, MO; 1:8,000 diluted in PBSM-T). Controls in all exper-
iments included wells containing only cells and wells containing all ingredients
except primary Abs, secondary Abs, or both. B. henselae OMPs and fetuin were
used as positive and negative controls, respectively. Experiments were performed
twice and in triplicate. Treatment differences were tested by Student’s t test (46).
For adherence inhibition, biotinylated bacteria were first pretreated with spe-
cific antibodies for 1 h at 37°C and washed before being used to infect the
monolayers as described above. Bacteria were biotinylated using the EZ-LinK
Sulfo-NHS-LC-biotinylation kit (Pierce, Rockford, IL) according to the manu-
facturer’s instructions (12). Bacteria preincubated with normal mouse serum
were used as controls, and wells receiving no bacteria were used as blanks.
Additional controls included wells containing all ingredients except the primary
or secondary antibodies. Biotinylated bacteria binding to monolayers were de-
tected using HRP-conjugated strepavidin (Pierce, Rockford, IL) and a substrate-
chromogen mixture consisting of 0.01% hydrogen peroxide in 0.1 mg/ml of
tetramethylbenzidine (Sigma, St. Louis, MO).
Immunoprecipitation experiments. For preparation of cell lysates used in the
immunoprecipitation of host cell Fn-bound purified Pap31, HUVECs exposed to
purified Pap31 (3 to 6 g/well) as described above were washed three times with
PBS, resuspended in lysis buffer {0.5% 3-[(cholamidopropyl)-dimethylammo-
nio]-1-propanesulfonate [CHAPS], 200 mM NaCl, 40 mM NaHCO3, 10% glyc-
erol, 1 mM phenylmethylsulfonyl fluoride, 5 g/ml leupeptin, and 5 g/ml pep-
statin A, pH 7.5}, and then incubated on ice for 30 min with intermittent
vortexing. Cells were homogenized on ice and then centrifuged at 12,000  g for
10 min at 4°C to remove particulate matter. The supernatant was collected,
transferred to fresh tubes, and stored at 70°C until use.
For immunoprecipitation, a mixture composed of 30 l of rabbit anti-Fn
polyclonal Abs (0.5-mg/ml solution; Sigma, St. Louis, MO), 30 l of cell lysates
(obtained as described above), and 210 l of cold immunoprecipitation (IPT)
buffer {0.1 M sodium phosphate [pH 7.2], 0.15 M NaCl, 2% [vol/vol] IGEPAL
CA-630 [trade name for (octylphenoxy)polyethoxyethanol], 0.1% SDS, and
0.02% sodium azide} was incubated overnight at 4°C with gentle shaking. Cell
lysates incubated with normal rabbit serum were used as negative controls. The
following day, Reacti-Bind protein A-coated plates (Pierce, Rockford, IL) were
washed three times with 200 l of IPT buffer for 5 min each with gentle shaking.
The immune complexes were then transferred to the washed protein A-coated
wells and incubated at room temperature for 4 h at 4°C with gentle shaking. After
incubation, the wells were washed five times with cold IPT buffer, and the bound
immune complexes were eluted with a reducing sample buffer (5; 0.3 M Tris-
HCl [pH 8.0], 2.5% SDS, 10% glycerol, 100 mM dithiothreitol) and subjected to
FIG. 2. Immunoblot of B. henselae whole cells that were either left
untreated () or treated () with trypsin (T), chymotrypsin (C), or
proteinase K (P). Protease-treated B. henselae whole cells were sub-
jected to SDS-PAGE and Western-blot analysis using mouse anti-
Pap31 antibodies as described in Materials and Methods.
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SDS-PAGE and Western blot analysis using mouse anti-Pap31 or rabbit anti-B.
henselae antibodies. In parallel experiments, purified B. henselae Pap31 was
preincubated with exogenous Fn at room temperature for 4 h, mixed with rabbit
anti-Fn polyclonal antibodies, and used in immunoprecipitation experiments as
described above. Normal rabbit serum was used as a negative control.
RESULTS
Molecular and immunological characterization of Pap31.
Immunoblots of protease-treated whole cells using anti-Pap31
antibodies revealed that Pap31 is susceptible to trypsin, chy-
motrypsin, and proteinase K digestion, indicating surface ex-
posure (Fig. 2). Expression of the mature Pap31 gene under
the control of the T7 promoter sequence (plasmid pCRT7/NT-
TOPO) was achieved with high yield and purity (Fig. 3 A). The
purified recombinant protein, which was confirmed to be
Pap31 by mass spectrometry analysis (data not shown), was
also demonstrated in Western blots with rabbit anti-B. henselae
and mouse anti-Pap31 antibodies (Fig. 3B and C, respectively).
Binding of Pap31 to Fn and mapping of Fn binding sites.
Ligand blotting revealed that Fn bound to purified Pap31 and
to a band in B. henselae OMPs identified as Pap31 by mass
spectrometric analysis (Fig. 4A). To further assess the affinity
FIG. 3. (A) Coomassie blue-stained SDS-PAGE gel of the ex-
pressed and purified recombinant Pap31. Lane 1, E. coli BL21(DE3)
pLYsS (pCRT7NT-TOPO); lane 2, E. coli BL21(DE3)pLYsS (pr-
Pap31), induced with IPTG; lane 3, purified rPap31. (B) Reactivities of
B. henselae OMPs (lane 1) and purified rPap31(lane 2) with rabbit
antibodies against live B. henselae. (C) Reactivities of B. henselae
whole cells (lane 1) and purified rPap31 (lane 2) with mouse anti-
Pap31. Arrows indicate native and recombinant Pap31.
FIG. 4. Binding of Pap31 to Fn. (A) Ligand blotting showing binding of B. henselae OMPs and purified Pap31 to Fn. (B and C) Binding of
purified Pap31 to thermolysin fragments. (B) Intact human Fn was digested with thermolysin for 4 h, resolved by SDS-PAGE, and Coomassie blue
stained (lane 1). Lane 2 contains broad-range molecular weight standards. (C) A duplicate gel was transferred to a nitrocellulose membrane and
incubated with purified Pap31 (40 g/ml) overnight at room temperature. Following washes, the bound Pap31 was detected with mouse anti-Pap31
antibodies. Positive bands with apparent molecular masses of 40, 34, 30, 29, and 24 kDa were detected (lane 1, bands 3, 4, 5, 6, and 7, respectively).
No corresponding bands were found in a similar blot incubated with PBSM-T buffer alone (lane 2). The N-terminal amino acid sequences of
thermolytic Fn fragments 1, 2, 3, 4, 5, 6, and 7, with apparent molecular masses of 120, 43, 40, 34, 30, 29, and 24 kDa, respectively, are given below.
The N-terminal amino acid sequence of fragment 4 (faint band) was inconclusive (inc.). Note that Pap31 bound to the  and  forms of both the
Hep-1 (fragments 6 and 7, respectively) and Hep-2 (fragments 5 and 3, respectively) domains of Fn. As expected, no binding was observed for the
cell-binding (fragment 1) and gelatin-binding (fragment 2) domains of Fn.
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of purified Pap31 for the Fn molecule, increasing amounts of
the purified protein were added to wells coated with Fn or a
fetuin control. Purified Pap31 bound to immobilized Fn in a
dose-dependent manner, and the levels of binding were con-
sistently higher for Fn than for the fetuin control (Fig. 5A).
Limited digestion of intact human Fn with thermolysin re-
vealed 11 distinct fragments with apparent molecular masses of
200, 160, 120, 43, 40, 34, 30, 29, 24, 22, and 17.5 kDa on an
SDS-PAGE gel (Fig. 4B, lane 1). For initial mapping of the Fn
domain(s) bound by purified Pap31, transblotted membranes
of thermolytic Fn fragments were overlaid with purified Pap31
in ligand blotting. Pap31 specifically bound the 40-, 34-, 30-,
29-, and 22-kDa thermolytic fragments but not the 200-, 160-,
120-, 43-, 24-, and 17.5-kDa fragments (Fig. 4C, lane 1). No
binding was observed in a blot overlaid with PBSM-T alone
(Fig. 4C, lane 2). N-terminal amino acid sequence analysis
revealed that the 29- and 22-kDa fragments contain the  and
 subunits of the Hep-1 domain of human Fn, respectively
(45). Our sequence analysis also indicates that the 30- and
40-kDa thermolytic fragments have identical N-terminal se-
quences and contain the  and  subunits of the Hep-2 domain
of human Fn, respectively (29, 44). These data suggest that
Pap31 binds efficiently to both the  and  subunits of the
Hep-1 and Hep-2 domains of Fn.
To further explore the binding of Pap31 to the Hep domains
of Fn and to extend our investigation to other Fn domains, we
tested the 120-kDa, 45-kDa, 40-kDa, and 30-kDa Fn fragments
(designated Fn-120, Fn-45, Fn-40, and Fn-30, respectively), as
well as Fn-PC and Fn-RN, as target molecules in ELISAs for
their abilities to bind Pap31 (Fig. 5B). Purified Pap31 signifi-
cantly bound intact Fn (P 	 0.01), the N-terminal Fn-30 (P 	
0.001) and C-terminal Fn-40 (P 	 0.001) fragments, and
Fn-RN (P	 0.001) (Fig. 5B). The level of adherence to Fn-PC
was about half the level of adherence to Fn-30, Fn-40, or
Fn-RN but not significantly different (P 
 0.05) from that to
the fetuin control (Fig. 5B). The levels of binding of Pap31 to
the Fn-120 and Fn-45 fragments and to the fetuin negative
control were similar and significantly (P 	 0.01) lower than
those to Fn, Fn-30, Fn-40, and Fn-RN (Fig. 5B). These results
suggest that Pap31 bound preferentially the N-terminal and
C-terminal Hep-binding domains of Fn and specifically the
12-14FnIII repeat modules.
Pap31 binds to Hep and shares a binding site with Hep on
the 13FnIII repeat module. To investigate whether Pap31 binds
FIG. 5. Characterization of Pap31 binding to immobilized Fn and Fn fragments. (A) Dose-dependent binding of rPap31 to intact human Fn.
Shown is binding of increasing amounts of rPap31 to wells coated with Fn (diamonds) or a fetuin control (triangles). Absorbance values are means
from representative experiments performed in triplicate. Error bars show the range of absorbance values. (B) Binding of rPap31 to wells coated
with Fn, Fn fragments, or a fetuin control. Absorbance values are means from representative experiments performed in triplicate. Error bars show
the range of absorbance values. (C) Binding of purified rPap31 to wells coated with Fn or Fn fragments in the presence of Hep. Binding was
expressed as the percentage of binding to wells in the absence of Hep. Bars represent means in triplicate wells  standard deviations.
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specifically to Hep, B. henselae OMPs, purified Pap31, and
positive and negative controls (Fn and EGF, respectively) were
incubated with Hep Sepharose Fast flow beads, and the eluted
Hp-bound protein fractions were analyzed by SDS-PAGE for
the presence of Pap31. Both purified Pap31 and the Fn positive
control bound Hep (data not shown). A band identified as
Pap31 by mass spectrometric analysis was also observed in the
OMP eluted fraction (data not shown). As expected, no bind-
ing was observed for the EGF negative control (data not
shown).
To test the effect of Hep on Pap31 adherence to the Hep-
binding domains of Fn, binding assays were performed using
wells coated with Fn, Fn-30 (Hep-1), Fn-40 (Hep-2), or Fn-RN
(12-14FnIII) in the presence of 1.6 M of Hep (porcine intes-
tinal mucosa; Sigma, St. Louis, MO) diluted in PBS. Hep had
a significant inhibitory effect on the binding of Pap31 to Fn
(11%) (P 	 0.05), Fn-30 (5%) (P 	 0.05), Fn-40 (25%) (P 	
0.01), and Fn-RN (48%) (P 	 0.01) (Fig. 5C). These results
suggest that Pap31 and Hep share the binding site on the
Hep-2 binding domain of Fn involving the 12-14FnIII repeat
modules. The data also indicate that Pap31 and Hep share
significantly more binding sites on the Hep-2 domain of Fn
than on the Hep-1 domain.
Binding of purified Pap31 to HUVECs. The binding of pu-
rified Pap31 to intact HUVEC monolayers was assessed by
ELISA and Western blot analysis. Purified Pap31, B. henselae
whole cells, and OMPs exhibited similar and significant bind-
ing to HUVECs (Fig. 6A). Comparatively, the binding of the
negative control, fetuin, was negligible (Fig. 6A). Purified
Pap31 also bound HUVECs in a dose-dependent manner,
whereas binding of the fetuin control remained low (Fig. 6B).
Lysates from HUVECs preexposed to purified Pap31 were also
investigated by Western blotting for the presence of the pro-
tein. A protein band corresponding to Pap31 was detected
when the blot was probed with anti-Pap31 polyclonal antibod-
ies (data not shown). No corresponding band was detected on
cell lysates derived from HUVEC monolayers exposed to the
buffer control only (data not shown).
To assess the functionality of anti-Pap31 antibodies in the over-
all adherence of B. henselae to host cells, biotinylated B. henselae
whole cells were first pretreated with the antibodies and then
tested for their ability to bind HUVEC monolayers. Pretreatment
of biotinylated B. henselae with increasing amounts of anti-Pap31
resulted in a significant (P 	 0.01) dose-response inhibition of
bacterial adherence (27, 46, and 53% reduction at 1:1,000, 1:100,
and 1:10 dilutions, respectively) (Fig. 6C). No significant differ-
ence (P
 0.05) was observed in the adherence of normal serum-
treated bacteria to HUVECs (Fig. 6D).
Immunoprecipitation. If Pap31 binds to Fn, then it should
coprecipitate with exogenous Fn as well as with endogenous
host cell Fn. Western blotting of a mixture of exogenous Fn
and Pap31 immunoprecipitated with anti-Fn antibodies showed
that purified Pap31 coprecipitated with exogenous Fn (Fig. 7A,
lane 1) when probed with anti-Pap31 antibodies. Precipitation
FIG. 6. Characterization of purified rPap31 binding to HUVECs by ELISA. (A) Binding of B. henselae whole cells, OMPs, rPap31, and a fetuin
control to HUVEC monolayers. (B) Dose-dependent binding of rPap31 to HUVECs. Shown is binding of increasing amounts of rPap31
(diamonds) or a fetuin control (triangles) to HUVEC monolayers. (C and D) Inhibition of B. henselae binding to HUVEC monolayers following
pretreatment of bacteria with mouse anti-Pap31 antibodies (C) or a control mouse serum (D). Experiments were performed as described in
Materials and Methods. For all experiments, absorbance values are means from representative experiments performed in triplicate. Error bars
show the range of absorbance values.
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with normal rabbit serum (negative control) did not show any
band corresponding to purified Pap31 (Fig. 7A, lane 2). Sim-
ilarly, anti-Fn polyclonal antibody immunoprecipitates of ly-
sates from HUVECs preexposed to Pap31 revealed a protein
band corresponding to Pap31 when probed with anti-Pap31 in
Western blots (Fig. 7B, lane 1). No corresponding band was
detected in similar normal rabbit serum immunoprecipitates
(Fig. 7 B, lane 2).
DISCUSSION
B. henselae infection initiates after trauma to the skin, sug-
gesting that adherence to host cells may be mediated by spe-
cific interactions between B. henselae surface proteins such as
Pap31 and components of the host ECM such as Fn and Hep.
Pap31 was previously shown to be involved in acquisition of
heme and thus may be an important virulence factor for B.
henselae (8, 53). Because heme receptor molecules are surface
exposed, we undertook to determine if Pap31 had another
virulence function as an adhesin to ECM. We have expressed
and purified B. henselae Pap31 with high yield and purity and
demonstrated its immunogenicity. We also demonstrated that
Pap31 acts as a potential ligand for Fn and Hep, indicating its
broad-range binding ability. Recognition of anti-Pap31 anti-
bodies in rabbits or mice vaccinated with live B. henselae or
purified Pap31, respectively, indicated that the protein is ex-
pressed in vivo and contributes to the humoral immune re-
sponse in the host defense against B. henselae. Taken together,
these data indicate that Pap31 is an adhesin with broad binding
ability and may be important in the interaction of B. henselae
with hosts.
The role of the humoral immune response in Bartonella
infections in cats is not clear (11). Differences in B. henselae
antigen-specific antibody responses have been reported in cats
and may be dependent on the strain or the individual cat’s
immune system (18, 36). Recently, Chenoweth and al. reported
virtually no Ab stimulation in cats by members of the heme-
binding protein (Hbp) family of proteins, which includes B.
henselae Pap31 (9), perhaps due to antigenic variation among
Hbp homologs (34). In the same study, no anti-lipopolysaccha-
ride (LPS) antibody was found in sera from B. henselae-in-
fected cats (9), and this lack of immunogenicity was attributed
to the composition of lipid A and attached long-chain fatty
acids of B. henselae LPS (51). The authors concluded that the
immunoevasive characteristics of LPS and members of the Hbp
family may be responsible for the pathogen’s ability to establish
long-term survival within its natural host (i.e., cats) (9). Our
present study provides clear and convincing evidence that Pap31
is recognized by rabbit and mouse humoral systems. Recognition
of purified Pap31 by cat immune systems is under investigation.
Fn, a multifunctional glycoprotein, consists of two similar
subunits ( and ) held together near the C terminus by two
disulfide bonds (Fig. 1). Each subunit comprises six distinct
domains, and the domains in turn are made up of amino acid
repeat modules known as FnI, FnII, and/or FnIII (Fig. 1) (35).
The five domains are referred to as Hep-1/Fib-1, Gel, Cell/
DNA, Hep-2, and Fib-2 because of their affinity for heparin
(Hep), gelatin (Gel), cell surface (Cell), or fibrin (Fib) and are
aligned from the NH2 to the COOH terminus in the above
order. Fn-30 (Hep-1) is the preferred binding site of most
bacteria and bacterial adhesins, while binding to Fn-40 (Hep-2)
by bacteria is uncommon (27). Recent studies mapped the target
region of the Hep-1 domain to the 4-5FnI repeat modules (25, 43).
We have shown in this study that Pap31 bound both thermolytic
Fn-30 and Fn-40 fragments (containing the  and  subunits of
the Hep-2 domain of human Fn, respectively) in ligand blotting.
We also mapped the binding site of the purified protein to the
13FnIII repeat module on the Hep-2 domain of Fn. Pap31 bound
significantly to the commercially purchased Fn-30 (Hep-1 do-
main), Fn-40 (Hep-2 domain), and Fn-RN (containing the central
cell-binding domain, the Hep-2 12-14FnIII repeat modules, and
the CS-1 region). The binding of Pap31 to the synthetic peptide
Fn-PC (located at the COOH-terminal end of the 14FnIII repeat
module) (14) was comparatively low. Pap31 did not bind Fn-120
(cell-binding domain) or Fn-45 (gelatin-binding domain), and
there is no report in the literature of involvement of the CS-1
region (part of RetroNectin) in bacterial adherence to Fn. The
above results provide clear evidence that the observed efficient
binding of Pap31 to the Hep-2 domain or RetroNectin was pre-
dominantly mediated by the 13FnIII repeat module on the Hep-2
domain of Fn.
The binding sites and/or mode of interactions of Hep with
the Hep-1 and Hep-2 domains of Fn have been reported for
several pathogens and adhesins (29, 38). Studies also indi-
cate that the cationic cradle of the 13FnIII repeat module of
Fn accounts for the major binding activity of Hep on the
Hep-2 domain of Fn (7, 28, 41). Recent studies identified
the 13FnIII repeat module of Fn as a primary binding site for
ShdA, a nonfimbrial adhesin from Salmonella enterica (29).
In addition, the binding of ShdA to 13FnIII was found to be
sensitive to the osmotic strength of the buffer, suggesting
that the binding involved ionic interactions. The significant
binding (P 	 0.001) of Pap31 to Fn-40 and Fn-RN was inhibited
(25% and 48%, respectively) by 1.6 M Hep, suggesting that
Pap31 and Hep share a similar binding site(s) involving the
13FnIII repeat module on the Hep-2 domain. Comparatively,
Hep had a reduced but significant (P 	 0.05) inhibitory effect
(5%) on the binding of Pap31 to Fn-30, suggesting few common
binding sites for Pap31 and Hep on Fn-30 (the Hep-1 domain
of Fn).
The ability of B. henselae to colonize host tissues may be
facilitated by bacterial surface proteins with high affinity for
ECM molecules, and the outcome of such colonization de-
FIG. 7. (A) Purified Pap31 was incubated with Fn for 1 h at 37°C, and
the complex was immunoprecipitated with anti-Fn (lane 1) or normal
rabbit serum (lane 2) as described in Materials and Methods. (B) Simi-
larly, lysates from HUVECs preexposed to purified Pap31were immuno-
precipitated with anti-Fn (lane 1) or normal rabbit serum (lane 2). Im-
munoprecipitates were subjected to Western blot analysis using mouse
anti-Pap31 antibodies.
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pends largely on the receptor/ligand interactions between the
host cells and the bacterium. Fn-binding proteins such as those
of Neisseria meningitidis promote the process of infection of
host cells, possibly via Fn bridging to 51 integrins (47).
Binding of Bartonella to different host cell types likely involves
adhesins that are variably expressed. A family of variably ex-
pressed and multifunctional B. quintana OMPs (Vomps) has
been shown to be involved in the binding of collagen (VompC)
and in autoaggregation (VompA) (52). Riess et al. identified a
B. henselae adhesin A (BadA) that mediates the binding of the
bacterium to ECM proteins and demonstrated that 1 inte-
grins are crucial for cell adhesion of B. henselae, possibly via Fn
bridging (39). This is in line with previous reports that show
that 1 integrins are required for YadA binding to host cells
(5). We demonstrated in this study the dose-dependent bind-
ing of purified Pap31 to HUVECs and coimmunoprecipitation
with Fn and anti-Fn. Consistent with these results, we detected
Fn on the surfaces of HUVEC monolayers when they were
probed with an anti-Fn monoclonal antibody (data not shown).
Our results also demonstrated that pretreatment of B. henselae
with anti-Pap31 inhibited the adherence of the bacterium to
HUVECs. Together these data suggest a role for Pap31 in the
adherence of the bacterium to HUVECs involving host cell
surface Fn.
Although GAGs such as Hep and HS have a prominent
role in cell-cell interactions and in cell growth, they are also
increasingly implicated as strong targets for bacterial adhe-
sion during early infection (1, 22, 23, 32, 49). GAGs have
been shown to participate in the GAG-mediated recruit-
ment of host ECM proteins, a novel strategy in bacterial
adherence and invasion (15). According to this strategy,
soluble HS, exposed during wound healing on the cell sur-
face, binds directly to bacterial surface molecules and serves
as a universal recruiting site for a wide range of the host
Hep-binding proteins, such as Fn, without producing sepa-
rate receptors for each protein. We have shown here that
Pap31 also bound Hep, suggesting that Hep could act as a
bridge between Pap31 and other ECM molecules such as Fn,
further enhancing B. henselae adhesion.
The expression of Opa proteins in N. gonorrhoeae has been
shown to promote the adherence of the bacterium to epithelial
cells (4, 50). Furthermore, one such Opa protein, OpaA, has
been shown to bind Fn and Hep and to be involved in bacterial
entry into host cells using a concerted action of Hep, Fn, and
integrin receptors (48). It is likely that expression of Pap31
during B. henselae infection may contribute similarly to bacte-
rial colonization and invasion, and as such, Pap31 may be a
potential target antigen for vaccine development and induction
of protective immunity using anti-adhesion strategies. Future
studies will seek to further elucidate the mode, site(s), and
mechanism(s) of Pap31 binding to Hep-binding domains of Fn,
map the region(s) on Pap31 involved in this binding, and assess
whether these interactions lead to bacterial colonization and in-
vasion or influence subsequent cellular functions in host cells.
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